No disclosed relationships extracted for GOVXyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Nothing on the wire mentions GOVX yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How GOVX has moved on past release days vs its typical ±5.2% day, and how often it closed up. Computed from daily closes — not a forecast.